RESEARCH HIGHLIGHT
July 2023

DCVC has released their inaugural Deep Tech Opportunities Report. It highlights their “organizing passion and principle” of investing in companies dedicated to disrupting and transforming industries like drug development. Creyon Bio is honored to be included among so many other amazing DCVC portfolio companies and to share about our efforts to quickly develop precision medicines for rare and common diseases, whether for millions of patients or for just one.

This recognition that deep tech has the potential to transform industries was, in part, what helped get Creyon Bio off the ground. Creyon was founded with the goal of solving the fundamental problem in drug development – it takes too long and costs too much to develop too few drugs.  DCVC Bio, one of our lead investors, aligned with our vision that the convergence of advances across many technologies presents an opportunity to disrupt drug development of Oligonucleotide-Based Medicines (OBMs) like antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), guide RNAs (gRNAs), RNA-editing guides, and aptamers.  Creyon Bio’s deep tech solution required the creation of purpose-built pharmacology datasets, a quantum-level understanding of OBM biophysics and the creation of ML/AI tools that tie these pieces together. With this deep tech solution, we can engineer for drug safety, something never before possible – ultimately radically lowering the cost and time required to rapidly develop new Oligonucleotide-Based Medicines. This transformative approach opens up drug development opportunities for any patient population size. And in a way that will make novel therapies accessible and available to people in need within the health care systems of the world today.